-
Thematic Analysis
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 – Top Themes and Predictions – Thematic Intelligence
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 Theme and Predictions Report Overview Total M&A deal value in the technology, media, and telecom (TMT) sector declined 46% in 2023, compared to the previous year. Software and services accounted for over 48% share of the total M&A deal value in 2023. The ‘Global Tech, Media, And Telecom (TMT) M&A Deals 2023 Theme and Predictions Report’ analyzes the top disruptive themes that drove M&A activity in the technology, media, and telecom (TMT)...
-
Analyst Opinions
Decarbonizing Maritime and Aviation Overview by Key Energy Transition Technologies and Case Studies, 2024 Update
Decarbonizing Maritime and Aviation Market Report Overview The automotive sector experiences a strong growth in demand for electric vehicles. However, the aviation and maritime sectors have been slow to decarbonize. To incentivize emission reductions, both sectors have set bold net-zero targets. However, according to the IEA, the sectors remain disoriented. Demand for cost-competitive and energy-dense fuels has led aviation and maritime to represent two of the most difficult to abate sectors. Both sectors will likely need to engage with a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-07264660 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-07264660 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-07264660 in Atopic Dermatitis (Atopic Eczema) Drug Details: PF-07264660 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Volrustomig in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Volrustomig in Gastric Cancer Drug Details: MEDI-5752 is under development for the treatment of solid...
-
Product Insights
NewGlomerulonephritis – Drugs In Development, 2024
Empower your strategies with our Glomerulonephritis – Drugs In Development, 2024 report and make more profitable business decisions. Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat (strep throat), immune diseases such as lupus, type 1 and type 2 diabetes, and viral infections such as HIV, hepatitis B virus, and hepatitis C virus. Risk factors include family...
-
Product Insights
NewCognitive Impairment – Drugs In Development, 2024
Empower your strategies with our Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Cognitive impairment is a condition characterized by a decline in cognitive functions, such as memory, attention, and problem-solving skills. It can range from mild to severe and may result from various causes, including aging, neurodegenerative diseases (like Alzheimer's), vascular disorders, traumatic brain injuries, infections, medication side effects, mental health issues, nutritional deficiencies, or environmental factors. Symptoms can include memory loss, confusion, difficulty...
-
Product Insights
NewFocal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024
Empower your strategies with our Focal Segmental Glomerulosclerosis (FSGS) – Drugs In Development, 2024 report and make more profitable business decisions. Focal segmental glomerulosclerosis (FSGS) is a rare kidney disease that causes scarring of the glomeruli, the tiny filters that remove waste from the blood. The scarring affects only some parts of some glomeruli, hence the name "focal segmental". FSGS can lead to protein loss in the urine, swelling in the body, high cholesterol, and kidney failure. FSGS can have different...
-
Product Insights
NewRetinopathy Of Prematurity – Drugs In Development, 2024
Empower your strategies with our Retinopathy Of Prematurity – Drugs In Development, 2024 report and make more profitable business decisions. Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder, which usually develops in both eyes, is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness. Risk factors for the development of ROP include prematurity, extremely low birth weight, and multiple...
-
Product Insights
NewRetinopathy – Drugs In Development, 2024
Empower your strategies with our Retinopathy – Drugs In Development, 2024 report and make more profitable business decisions. Retinopathy is any damage to the retina of the eyes, which may cause vision impairment. Retinopathy often refers to retinal vascular disease, or damage to the retina caused by abnormal blood flow. Retinopathy, or retinal vascular disease, can be broadly categorized into proliferative and non-proliferative types. Frequently, retinopathy is an ocular manifestation of a systemic disease such as diabetes or hypertension. The Retinopathy...